Wealth Advisory Solutions LLC Cuts Position in Novo Nordisk A/S $NVO

Wealth Advisory Solutions LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 33.4% during the third quarter, HoldingsChannel reports. The institutional investor owned 28,577 shares of the company’s stock after selling 14,300 shares during the quarter. Wealth Advisory Solutions LLC’s holdings in Novo Nordisk A/S were worth $1,586,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in NVO. Werba Rubin Papier Wealth Management lifted its holdings in shares of Novo Nordisk A/S by 4.1% during the 2nd quarter. Werba Rubin Papier Wealth Management now owns 4,378 shares of the company’s stock valued at $302,000 after acquiring an additional 173 shares in the last quarter. Atwood & Palmer Inc. lifted its stake in shares of Novo Nordisk A/S by 31.8% during the second quarter. Atwood & Palmer Inc. now owns 737 shares of the company’s stock worth $51,000 after purchasing an additional 178 shares in the last quarter. Beacon Financial Group grew its stake in shares of Novo Nordisk A/S by 4.3% in the third quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock valued at $239,000 after buying an additional 178 shares in the last quarter. Copeland Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 47.3% during the second quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock worth $40,000 after purchasing an additional 186 shares in the last quarter. Finally, Bigelow Investment Advisors LLC boosted its stake in shares of Novo Nordisk A/S by 6.9% in the second quarter. Bigelow Investment Advisors LLC now owns 3,084 shares of the company’s stock valued at $213,000 after purchasing an additional 200 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo says oral GLP‑1 pills could capture over one‑third of the overall GLP‑1 market by 2030, a larger share than previously expected — this boosts long‑term revenue upside for NVO’s new oral Wegovy offering and validates the company’s market expansion strategy. Novo Nordisk sees oral pills capturing over third of GLP‑1 market by 2030
• Positive Sentiment: CEO Mike Doustdar highlighted Wegovy’s cardiovascular benefits on CNBC’s Mad Money, reinforcing clinical value beyond weight loss — a narrative that supports premium pricing and broader prescribing. Novo Nordisk CEO: Wegovy not only reduces your weight, but it also shows cardiovascular benefits
• Positive Sentiment: Market reaction to the Wegovy pill rollout pressured rival Eli Lilly shares (investors priced increased competition), which can be seen as validation that Novo’s oral product is meaningful industry competition and could support NVO share strength. This ETF Is Proof That the Healthcare Rebound Is Real (NVO)
• Neutral Sentiment: Academic/real‑world signals: a study linked GLP‑1 RA use to lower household spending on alcohol and tobacco — evidence that these drugs may change broader health/consumption patterns, but direct revenue implications are uncertain. Novo Nordisk’s GLP‑1 RA linked to lower household spending
• Neutral Sentiment: Analyst/investor commentary (Fundsmith, Zacks, Seeking Alpha) shows elevated attention to NVO — increased scrutiny and flows can amplify moves but cut both ways depending on next data/guide. Fundsmith Equity Fund’s Thoughts on Novo Nordisk (NVO)
• Neutral Sentiment: Unusual options activity noted on NVO — elevated options volume can signal directional bets or hedging ahead of catalysts (product rollouts, guidance); watch implied vol and open interest. Looking At Novo Nordisk’s Recent Unusual Options Activity
• Negative Sentiment: Management warned as many as 1.5 million U.S. patients may be using compounded, unapproved GLP‑1 alternatives — these cheaper substitutes have already captured meaningful demand and represent a near‑term revenue headwind and pricing pressure for NVO. Novo Nordisk CEO flags 1.5 million US users of compounded GLP‑1 drugs

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $59.83 on Tuesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $93.80. The firm has a fifty day moving average of $49.87 and a 200-day moving average of $55.15. The company has a market cap of $267.12 billion, a price-to-earnings ratio of 17.39 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The firm had revenue of $11.79 billion during the quarter, compared to analyst estimates of $11.98 billion. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Rothschild & Co Redburn upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research note on Tuesday, December 23rd. Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday, December 29th. Hsbc Global Res lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. Finally, Berenberg Bank upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $56.21.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.